May 19, 2015 at 07:52 | Source: Moneycontrol.com
Mangalore Chemicals | Suzlon Energy | ONGC | Eros | CHD Developers | NIIT Tech | L&T Finance | GMR | Bharti Airtel | Tata Steel and Power Grid are stocks | which are in news today.
May 08, 2015 at 10:39 | Source: Moneycontrol.com
Auto stocks like Ashok Leyland, Tata Motors, Maruti Suzuki India, Mahindra & Mahindra, TVS Motor Company and Bajaj Auto will get astro support, says Satish Gupta of astrostocktips.
Apr 30, 2015 at 13:15 | Source: CNBC-TV18
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have HDFC, VRL Logistics, Exide, Infosys, TCS, RPG Life and Biocon.
Apr 30, 2015 at 12:10 | Source: CNBC-TV18
Biocon's Kiran Mazumdar Shaw said the company deliberately took a hit on its topline in order to rationalize products. Biocon is focusing towards being a specialized products player.
Apr 30, 2015 at 10:35 | Source: Moneycontrol.com
Auto stocks like Ashok Leyland, Maruti Suzuki India, TVS Motor Company, Hero Motocorp, Tata Motors will get astro support, says Satish Gupta of astrostocktips.
Apr 30, 2015 at 09:06 | Source: Moneycontrol.com
Biocon's fourth quarter profit after tax climbed 78 percent year-on-year to Rs 201 crore led by exceptional gains of Rs 105.06 crore (on account of sale of shares of Syngene).
Apr 30, 2015 at 08:09 | Source: Moneycontrol.com
Heres a list of top 10 stocks that are in news due to their Q4 earnings and controversy.
Apr 30, 2015 at 07:59 | Source: CNBC-TV18
Infosys | ONGC | Bosch | ONGC | Supreme Infra | JSPL | IDFC | GAIL | Bank Of Maharashtra | OBC | Dena Bank | PNB Gilts | Man Industries | RPG Life Sciences | Alstom India | Hexaware and Varun Shipping are stocks, which are in the news today.
Apr 29, 2015 at 08:54 | Source: CNBC-TV18
Biocon's fourth quarter (January-March) profit is seen falling 8.5 percent year-on-year to Rs 103.35 crore due to weak operational numbers, according to the average of estimates of analysts polled by CNBC-TV18.
Apr 28, 2015 at 11:32 | Source: Reuters
The just completed Ranbaxy deal, its biggest to date at USD 3.2 billion, has given India's biggest drugmaker sufficient scale in generics and emerging markets to think about its next step - beefing up expertise in higher margin products and gaining a bigger global presence.